Ignite Creation Date:
2025-12-24 @ 9:46 PM
Ignite Modification Date:
2026-02-22 @ 4:14 PM
Study NCT ID:
NCT01590732
Status:
COMPLETED
Last Update Posted:
2018-09-19
First Post:
2012-05-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Mycosis Fungoides | View |
| None | Recurrent Anaplastic Large Cell Lymphoma | View |
| None | Recurrent Angioimmunoblastic T-Cell Lymphoma | View |
| None | Recurrent Enteropathy-Associated T-Cell Lymphoma | View |
| None | Recurrent Hepatosplenic T-Cell Lymphoma | View |
| None | Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified | View |
| None | Refractory Anaplastic Large Cell Lymphoma | View |
| None | Refractory Angioimmunoblastic T-Cell Lymphoma | View |
| None | Refractory Enteropathy-Associated T-Cell Lymphoma | View |
| None | Refractory Hepatosplenic T-Cell Lymphoma | View |
| None | Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified | View |
Keywords: